INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving ImmunityBio, Inc. and its officers or directors [1]. Group 1: Company Overview - ImmunityBio, Inc. is listed on NASDAQ under the ticker IBRX [1]. - The company recently announced updated Phase 2 clinical results for a chemotherapy-free combination immunotherapy regimen targeting second-line recurrent or progressive glioblastoma [3]. Group 2: Recent Developments - On January 23, 2026, ImmunityBio reported that the median overall survival, a primary endpoint for its clinical trial, has not yet been reached [3]. - Following the announcement of the clinical results, ImmunityBio's stock price decreased by $0.89 per share, representing a 12.13% decline, closing at $6.45 per share [3]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering significant damages for victims of securities fraud and corporate misconduct [4].